$IMRX

Hall Brett Matthew purchased $25K of IMRX

Hall Brett Matthew (CHIEF SCIENTIFIC OFFICER) purchased 6,035 shares of Immuneering Corp (IMRX) at $4.15 on 2026-06-15.

Original reporting
SEC EDGAR · Hall Brett Matthew
Published Jun 16, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:24 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IMRX
Neutral
low confidence
Mentioned
$IMRX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMRXNeutralLow
01

Why it matters

The newest fact is the disclosed open-market purchase (6,035 shares at $4.15) and the post-transaction holdings (382,531 shares).

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no accompanying operational or financial update in the text.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still lacks context on prior trading history, motivations, and whether the purchase size is meaningful versus typical insider activity.

Relevance 4/10Novelty 3/10Timing: filed 2026-06-16, transaction dated 2026-06-15

Background

This is an SEC Form 4 insider transaction for Immuneering Corp (IMRX) by its Chief Scientific Officer.

Company-level read

Ticker impact

$IMRXNeutralLow confidence
Context

Immuneering Corp insider Form 4 shows Chief Scientific Officer Hall Brett Matthew bought 6,035 shares at $4.15 on 2026-06-15.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless followed by additional disclosures.

Evidence & confidence

Form 4 insider buys are informational but typically do not change earnings, guidance, or regulatory/clinical timelines; the article provides no new company-specific operational update.

Market effects

Minimal; this is a single-company insider transaction with no sector-wide signal provided.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine, tax-related, or part of personal liquidity planning, so the signal may be overstated.

Key entities

  • Immuneering Corp

    Company whose insider transaction is disclosed on Form 4.

  • Hall Brett Matthew

    Chief Scientific Officer who purchased shares in an open-market transaction.

Related articles

$IMRXMedAI 9/10

Immuneering’s Pancreatic Cancer Drug Shows 17.3-Month Survival as Phase III Trial Nears

Immuneering (NASDAQ:IMRX) reported updated Phase 2 results for atebimetinib plus modified gemcitabine nab-paclitaxel in first-line pancreatic cancer. CEO Ben Zeskind said median overall survival was 17.3 months in the original (n=34) cohort and remained 17.3 months in an expanded (n=55) cohort; Phase 3 MAPKeeper 301 is recruiting, with first dosing planned for mid-2026 and topline in 2028.

$IMRXMedAI 9/10

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering (IMRX) reported updated Phase 2a data at ASCO for atebimetinib plus modified gemcitabine/nab-paclitaxel in 55 first-line metastatic pancreatic cancer patients. Median overall survival was 17.3 months vs 8.5 months in the MPACT standard-of-care study, with 8.3-month PFS, 82% disease control, and 36% ORR. Grade 3+ treatment-related AEs were limited to two chemotherapy-related categories; 84% maintained/gained weight at 3 months. MAPKeeper 301 Phase 3 is recruiting, with first dosing ex